Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dexmedetomidine · 1 trial · 1 indication
Measured with mass spectrometry
Measured with mass spectrometry
Measured with mass spectroscopy
Measured with mass spectroscopy
| Arm | Type | Description |
|---|---|---|
| Dexmedetomidine Cross-Over Placebo | PLACEBO_COMPARATOR | - |
| Dexmedetomidine Cross-Over Treatment | ACTIVE_COMPARATOR | - |
| Dexmedetomidine & Midodrine Cross-Over Treatment | ACTIVE_COMPARATOR | - |
| Dexmedetomidine & Midodrine Cross-Over Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Dexmedetomidine | DRUG | Treatment |
| Dexmedetomidine and Midodrine | DRUG | Treatment |
| Placebo | OTHER | Placebo |
Inclusion Criteria: Potential participants must satisfy the following criteria to be enrolled in the study: 1. In the opinion of the Principal Investigator, participants must be fluent in English and be able to understand the informed consent form approved by the Institutional Review Board (IRB). ...
Top 20 of 24 competitors
Dexmedetomidine is an investigational small molecule being studied for Alzheimer Disease. It is being evaluated for its potential to enhance glymphatic function, which may help clear waste products from the brain. The drug is in Phase 1 clinical development and is not yet approved for any use.
Dexmedetomidine is being developed by Cognition Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker CGTX. The company is conducting clinical research on this drug for the treatment of Alzheimer Disease.
Dexmedetomidine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for Alzheimer Disease.
Dexmedetomidine has one completed Phase 1 clinical trial with the identifier NCT07432997, titled "Pharmacological Enhancement of Glymphatic Function in Humans." The trial enrolled 31 participants, including healthy volunteers, and was conducted in the United States. It was a double-blind, placebo-controlled study.
Dexmedetomidine is being studied for its potential to enhance glymphatic function in the brain. The glymphatic system is a waste clearance pathway that removes toxic proteins, which may be relevant to Alzheimer Disease. The drug is thought to improve this clearance process, though its exact mechanism is still under investigation.
Dexmedetomidine is the drug name used in clinical development. The drug may also be referred to by its chemical salt form, dexmedetomidine hydrochloride, which is a common formulation for small molecule drugs. However, the clinical trial data for this asset uses the name Dexmedetomidine.